Moving Forward with Capecitabine: a Glimpse of the Future

Moving Forward with Capecitabine: a Glimpse of the Future Laura Biganzoli, Miguel Martin, Chris Twelves Oncologist 2002; 7(Suppl 6): 29-35 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Appreciate the emerging role of capecitabine monotherapy in the treatment of advanced, refractory breast cancer. Explain the current status of capecitabine monotherapy as first or second line therapy in patients with advanced breast cancer. Describe the rationale and current status of capecitabine combination treatment of breast cancer. Balance the safety profile of capecitabine with available alternative treatment options for the treatment of advanced breast cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 27, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Nov. 27, 2002 Date Credit Expires: June 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Incorporating Oral Capecitabine into the Treatment of Breast Cancer.